Innovent Biologics Submits IND Application for IBI362 (OXM3), a Novel GLP-1/Glucagon Receptor Dual Agonist, to CDE

On February 15, the clinical trial application for IBI362 for injection submitted by Innovent Bio was accepted by the CDE.

IBI362 (OXM3), developed by Eli Lilly, is a potential best-in-class dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist currently in mid-stage clinical development. On August 22, 2019, Innovent Bio and Eli Lilly entered into a strategic collaboration to jointly advance the development and commercialization of OXM3 in China.

OXM3 is a natural peptide analog derived from the post-transcriptional processing of the proglucagon gene in the intestine. Similar to native peptides, OXM3 binds to and activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR).

OXM3 is a long-acting molecule administered via once-weekly injection. In early-stage clinical trials, the OXM3 oxyntomodulin molecule has demonstrated efficacy in controlling blood glucose levels and reducing body weight in subjects, highlighting its potential therapeutic benefits for the treatment of diabetes, obesity, and non-alcoholic steatohepatitis (NASH).